Phosphatidic Acid and Magnesium Composition for PMS Symptom Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compositions for alleviating premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) symptoms are inadequate, as they do not effectively address the hormonal and emotional changes associated with these conditions, and there is a need for improved treatments that can be safely administered and easily integrated into daily life.
Innovation Solution
A pharmaceutical/nutritional composition comprising at least 2% phosphatidic acid or its salts combined with a bio-available form of magnesium, which can be administered orally or intravenously, and may include additional excipients to enhance handling and shelf life, allowing for incorporation into food and beverages, providing a multi-part regimen for symptom relief.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing PMS/PMDD treatments are used, then some symptom relief is achieved, but the relief is inadequate and does not effectively address hormonal and emotional changes
Solution Approach 1:
The patent combines phosphatidic acid with magnesium in a composite formulation to address multiple aspects of PMS/PMDD symptoms simultaneously. This composite approach allows the composition to effectively address both physical and emotional symptoms, resolving the limitation of existing single-ingredient treatments that fail to provide comprehensive relief.
2Reliability
If treatments are administered frequently to maintain continuous symptom relief, then effectiveness is improved, but pain and safety concerns arise
Solution Approach 1:
The patent employs a multi-part regimen that can be dynamically adjusted in frequency and dosage based on the patient's symptom severity and response. This dynamic approach allows continuous symptom relief while minimizing administration frequency to avoid pain and safety issues, replacing the need for frequent aggressive interventions with a flexible, responsive treatment schedule.
3Reliability
If treatments are made more potent to improve symptom relief, then effectiveness increases, but safety problems and adverse effects increase
Solution Approach 1:
The patent utilizes phosphatidic acid and magnesium, both of which have established safety profiles and known beneficial effects on hormonal balance and emotional regulation. By selecting ingredients with appropriate pharmacokinetic parameters and safe dosage ranges, the composition achieves effective symptom relief without the safety problems and adverse effects associated with more potent but riskier treatments.
Data Source
AI summary
The present invention discloses pharmaceutical/nutritional compositions for use in alleviating symptoms associated with premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD). The pharmaceutical/nutritional compositions include at least 2% (w/w) phosphatidyl-L-serine, or salts thereof, out of a total effective composition, as a first effective ingredient; and a suitable amount of at least one bio-available form of magnesium as a second effective ingredient. Preferably, the bio-available form of magnesium is magnesium oxide, magnesium citrate, magnesium hydroxide, magnesium stearate, or a magnesium salt of the phosphatidyl-L-serine. Preferably, the composition further includes a pharmaceutical or nutritional excipient. Preferably, the total effective composition is administrable in a multi-part regimen. Preferably, the total effective composition is administrable by intravenous or oral delivery. Preferably, the pharmaceutical/nutritional composition further includes at least 2% (w/w) phosphatidic acid, or salts thereof, out of the total effective composition, as a first effective ingredient.